Roy M. Fleischmann, MD and primary investigator for SELECT-COMPARE, the phase III clinical trial of Rinovoq, AbbVie’s oral once-daily JAK inhibitor for adults with moderate to severely active rheumatoid arthritis who have had an inadequate response or intolerance to...